Format

Send to

Choose Destination
Clin Transplant. 2017 May;31(5). doi: 10.1111/ctr.12947. Epub 2017 Mar 31.

Lactobacillus rhamnosus GG probiotic enteric regimen does not appreciably alter the gut microbiome or provide protection against GVHD after allogeneic hematopoietic stem cell transplantation.

Author information

1
Department of Medicine, Rutgers Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ, USA.
2
Department of Pathology and Laboratory Medicine, Rutgers Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ, USA.
3
Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ, USA.
4
Division of Cancer Medicine, Departments of Genomic Medicine and Stem Cell Transplantation Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Abstract

Graft-versus-host disease (GVHD) is a major adverse effect associated with allogeneic stem cell transplant. Previous studies in mice indicated that administration of the probiotic Lactobacillus rhamnosus GG can reduce the incidence of GVHD after hematopoietic stem cell transplant. Here we report results from the first randomized probiotic enteric regimen trial in which allogenic hematopoietic stem cell patients were supplemented with Lactobacillus rhamnosus GG. Gut microbiome analysis confirmed a previously reported gut microbiome association with GVHD. However, the clinical trial was terminated when interim analysis did not detect an appreciable probiotic-related change in the gut microbiome or incidence of GVHD. Additional studies are necessary to determine whether probiotics can alter the incidence of GVHD after allogeneic stem cell transplant.

KEYWORDS:

graft-versus-host disease; gut microbiome; hematopoietic stem cell transplantation; probiotics

PMID:
28256022
DOI:
10.1111/ctr.12947
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center